🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — October 29, 2026

Across 50 Q3 2026 filings, revenue growth was broad (median roughly +9% YoY) but earnings quality diverged sharply: margin compression and one-time items dominated, with 12+ companies posting YoY net income declines despite higher sales. The dominant theme is cost inflation outrunning revenue — labor, fuel, interest and acquisition amortization — with gross margin compression flagged at Belden (-2.6 pts), Chipotle (labor 25.2%→25.7% of revenue), Ecolab (cost of sales +14.2% vs sales +12.7%), Cimpress, Pilgrim's Pride (7.2% vs 13.9%) and Titan. Interest expense was a recurring swing factor: it crushed Ecolab EPS (-4.9%), CSW Industrials ($1.3M→$12.5M), Cohu ($0.4M→$5.1M) and ProPetro, while falling sharply at Norwegian, Gen Digital and TechnipFMC, flattering EPS there. Energy/LNG names (Cheniere complex, NextDecade, Sabine Pass) showed violent derivative-driven earnings swings with operating cash flow diverging from reported net income, and several balance sheets deteriorated (Bausch goodwill impairment $1.43B, Blackstone Mortgage $327M loss, Century Communities negative operating cash flow). Capital allocation was aggressive and debt-funded at Crocs, Chipotle ($1.46B buybacks), Tradeweb ($447M vs $0.8M) and CPKC, while dividends held steady even at loss-making Blackstone Mortgage. Net: a 'growth without operating leverage' quarter where buyback-driven EPS and non-cash items mask underlying margin and leverage stress.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 29, 2026

The 11 DEF 14A filings reveal a stark divide between large-cap stability and micro-cap distress, with governance actions often serving as distress signals. Cisco stands out with record FY2026 revenue of $63.3B (+12% YoY) and GAAP EPS up 31%, yet its non-GAAP operating margin expanded only 40 bps, highlighting earnings quality concerns. Meanwhile, five micro-cap companies (Vivos, Kindly MD, Ocean Power, Owens & Minor, Fly-E) are pursuing reverse splits or highly dilutive financings to address listing deficiencies or liquidity crunches, with potential dilution ranging from 25.9% to over 1,500% of current shares. A common theme is the use of equity incentive plan expansions (Vivos, Bonk, enVVeno) to preserve cash, often accompanied by significant share reserve increases (Bonk +70.3%). Insider control is pronounced at VASO (42.06% insider voting power) and Ocean Power (investors could hold 25.9% post-conversion), raising governance risks. Upcoming meetings cluster in December 2026, with key catalysts including reverse split approvals (Owens & Minor Dec 1, Vivos Dec 2) and say-on-pay votes (Cisco, Guidewire, enVVeno) that could signal shareholder unrest.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 29, 2026

The October 29, 2026 IPO pipeline is dominated by small-cap and micro-cap registrations, with three S-1 filings spanning a blank-check vehicle, a DFW stone fabricator, and a distressed resale registration. The common thread is governance and structural risk: Redwoods Acquisition Corp II offers a standard SPAC unit with 100% redemption and a 12-month clock, KAT Construction Services presents a dual-class structure where Series A preferred carries ~96.8% voting power despite raising only ~$20M, and La Rosa (now Stratum Holdings) registers up to 69.7M shares under a $1B equity line but expects only ~$30M in gross proceeds while flagging late 10-K/10-Q filings and a pivot to a single-lessee GPU leasing business. Period-over-period comparisons are largely unavailable in the enriched data, but the filings reveal a clear pattern of capital-structure complexity and disclosure gaps rather than operational momentum. Sentiment is neutral for the two new registrants and negative for La Rosa, with materiality scores of 6, 6, and 7 respectively. The absence of insider buying, dividends, or buybacks across all three filings underscores that these are capital-raising events, not shareholder-return stories. Investors should focus on deal terms, governance protections, and the credibility of forward-looking business pivots rather than near-term fundamentals.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 29, 2026

The October 29, 2026 US trading-suspension stream is dominated by listing-standard stress: three of four filings involve Nasdaq compliance failures or delistings, while one is a voluntary NYSE-to-TXSE transfer. The most acute events are Glucotrack's confirmed delisting (trading suspended at the open on October 30, 2026) and Propanc Biopharma's imminent delisting (effective November 2, 2026 absent an appeal by October 30, 2026), both driven by the $1.00 minimum bid price rule and complicated by prior reverse splits. Greenland Energy Company (Pelican Holdco) remains listed but has an outstanding majority-independent-director deficiency with a cure period running to the earlier of its next annual meeting or October 20, 2027, though its audit committee deficiency was cured on October 27, 2026. Cullen/Frost's move is fundamentally different: a board-authorized, voluntary transfer of both its common and Series B preferred listings to the Texas Stock Exchange, with NYSE trading ending November 11 and TXSE trading beginning November 12, 2026, under the same symbols. Across the stream, the common thread is exchange-listing risk management: micro-caps face forced delisting and OTC migration, while a large Texas bank is opting into a regional exchange for strategic reasons. Near-term catalysts are concentrated in the next 72 hours (Glucotrack suspension, Propanc appeal deadline) and the next two weeks (Cullen/Frost listing transition).

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — October 29, 2026

The October 29, 2026 filing batch is dominated by executive and board turnover, with 44 filings spanning CFO successions, CEO appointments, director additions and retirements. Key CFO transitions include Norwegian Cruise Line (Kempa to Montana, effective Jan 1, 2027), Strategy Inc (Kang out Nov 5, Virasteh in Jan 1, 2027), Summit Hotel (Nieves in Nov 1), Southern Missouri Bancorp (Chkautovich out Nov 7, Funke interim), and PennyMac (Ryan in Jan 1, 2027). CEO changes include Clorox (Fabian Garcia effective Jan 5, 2027, replacing Linda Rendle for health reasons), Estrella Immunopharma (Cynthia Pussinen, Oct 25), Shutterstock (founder Jon Oringer returns as CEO, Oct 28), and Hormel (Ghingo assumes CEO role, Oct 26). Board refreshment is broad, with 15+ director appointments across sectors, including several high-profile additions: Meta's former VP of Infrastructure to Aehr Test, former Fluor CEO to Marathon Petroleum, and former Cigna Chief Health Officer to Teva. Financial disclosures in the batch show mixed performance: Monolithic Power Systems posted record Q3 revenue of $1.2B (+63% YoY) and raised Q4 guidance, while BCB Bancorp reported a $132.5M quarterly loss and a $115M credit provision, and Bright Horizons swung to a $230.7M net loss on $294M impairment. Insider activity is limited but notable: CEO/CFO option grants at Ionetix and a voluntary salary cut by Coastal Financial's CEO. Overall, the batch signals a wave of leadership transitions that could drive strategic shifts, with several companies facing financial stress and others capitalizing on growth opportunities.

44 high priority 44 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 29, 2026

The October 29, 2026 board-room batch is dominated by orderly C-suite successions and board refreshes rather than abrupt departures: 12+ officer changes and 15+ director appointments/resignations were disclosed, with most companies explicitly stating no disagreements. A clear succession wave is forming for early 2027 — Clorox (CEO Jan 5), NCLH (CFO Jan 1), PennyMac (CFO Jan 1), Strategy Inc (CFO Jan 1), Lionsgate (CFO term ends Jan 31), Forestar (Exec Chair Nov 1) — creating a catalyst calendar concentrated in Q4 2026–Q1 2027. Financial disclosures in the batch show a sharp bifurcation: AI/data-center semiconductor demand is booming (Monolithic Power revenue +63.1% YoY, first $1B quarter; Aehr adding Meta infrastructure expertise), while consumer/industrial names show margin pressure (Harley-Davidson HDMC revenue -10%, operating income -18%; Floor & Decor comps -1.4%; Saia operating ratio widened 170 bps). Governance stress is visible in several names: BCB Bancorp posted a $132.5M quarterly loss with a $115M credit provision and C-suite reorganization; Strategy Inc's CFO exit coincides with negative BTC Yield of (3.7)% and a $(2.03)B BTC loss; Shutterstock cancelled its Q3 earnings call amid a strategic review while reinstalling its founder as CEO. Insider/compensation signals skew toward alignment: Coastal Financial's CEO voluntarily cut his salary from $874K to $500K, while Ionetix and Estrella used equity-heavy, milestone-based pay to conserve cash.

44 high priority 44 total filings
· daily

USA Insider Trading Pulse — October 29, 2026

Today's 50 insider filings reveal a market bifurcation: while several executives cashed out near highs, a notable cluster of bullish bets emerged in financials and small caps. The most striking signal is Capital One CEO Richard Fairbank's $17M sale under a 10b5-1 plan, part of a broader wave of insider selling that also saw Vesta CFO Juan Felipe Sottil Achutegui dump $1.14M and Radware executives offload shares. Conversely, Truist CEO Michael Lyons purchased $1.21M in stock, and Agora CEO Zhao Bin bought $42.7K, signaling confidence in beaten-down names. A massive coordinated disposal at Cloopen Group (CEO, CFO, CTO, and directors) suggests a significant corporate event, while Sea Ltd insiders exercised $32M in options with minimal sales, indicating long-term conviction. The banking sector showed mixed insider activity, with buys at Bank First, Shore Bancshares, and Northpointe Bancshares contrasting with sales elsewhere. Overall, insider sentiment is net negative, but selective buying in financials and small caps may signal early value opportunities.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 29, 2026

The US M&A & Takeover Activity stream for October 29, 2026, is dominated by SPAC lifecycle events and a strategic divestiture. UNIFI Inc. completed a $60 million sale of non-strategic real estate, using net proceeds to fully repay its $55.5 million term loan, deleveraging its balance sheet and improving liquidity without impacting production capacity. Among SPACs, Lakeshore Acquisition III Corp. received a fourth $67,500 extension payment from CPRO Korea, pushing its merger deadline to December 1, 2026, signaling persistent delays but continued counterparty commitment. Inflection Point Acquisition Corp. VI achieved SEC effectiveness of its Form S-4 for the Quantum Space combination, a critical milestone that brings the deal closer to a shareholder vote, though the target's flagship vehicle remains pre-revenue. Rising Dragon Acquisition Corp. issued an $11,188.68 promissory note to SZG Limited to fund a trust extension, highlighting ongoing financing needs for its January 2025 merger agreement. Overall, the filings reflect a mix of balance-sheet strengthening and SPAC deal progression, with no period-over-period financial comparisons or insider activity disclosed, limiting trend analysis. The absence of insider transactions and capital allocation updates suggests a quiet period for management conviction signals.

4 high priority 4 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 29, 2026

The overnight US SEC stream for 2026-10-28 to 2026-10-29 is dominated by a heavy flow of routine Form 4 insider filings, particularly ServiceNow equity grants and a large cluster of Weave Communications share disposals to the issuer, alongside a smaller set of market-moving 10-Q, 8-K and 6-K earnings and balance-sheet disclosures. The most material period-over-period developments are ASE Technology's sharp Q3 2026 revenue (+45% YoY) and profit surge (+148% YoY) offset by a rising net debt-to-equity ratio (0.47 to 0.66) and a jump in interest-bearing debt to NT$406,461 million, Alphabet's 24.6% revenue growth overshadowed by a 24.3% net income decline driven by an $8.2 billion other-expense swing, and Ford's Q3 revenue slip (-2.0%) and net income drop (-16.3%) despite a 13.5% rise in nine-month net income. Among smaller issuers, Chilwa Minerals (1.67 quarters of funding) and Resolution Minerals (0.2 quarters) carry acute liquidity concerns, while Escalade and Proto Labs posted record or near-record results with cautious Q4 signals. Insider activity skews toward disposals at Weave and sell-side 10b5-1 plans at Voya and MediaAlpha, while open-market buying at TTM Technologies (CEO and director purchases near $90) stands out as the sole clear conviction signal. Portfolio-wide, growth is strong in AI/EMS hardware and advertising-linked names but margins and funding quality are deteriorating in several places, and the Trump Media/TAE merger vote on 14 December 2026 is the largest scheduled binary event in the window.

34 high priority 16 medium 50 total filings
· daily

Biotech Small-Cap Approvals — October 28, 2026

This period's stream of five FDA approvals on October 28, 2026 (window dated October 21-26 approval records) comprised zero NMEs, zero label expansions, and five 'Other' approvals classified as FALLBACK-type actions, including four generic/biosimilar-labeled actions (valganciclovir from Alembic, teriparatide from Dr. Reddy's, trimethoprim from Bionpharma, amlodipine besylate from Cadila Pharmaceuticals) and one NME-labeled action (aflibercept-abzv from Sandoz, marketed as ENZEEVU). Signal mix is 1 bullish, 0 bearish, 4 neutral. There is no dominant therapeutic area cluster: the approvals span anti-infective (valganciclovir, trimethoprim), bone/endocrine (teriparatide), ophthalmology (aflibercept), and cardiovascular (amlodipine). The highest-conviction item is Sandoz's aflibercept-abzv (ENZEEVU), which carries the only bullish signal and is the only approval in this set with NME-level commercial relevance, though the source data does not confirm its formal NME/biosimilar pathway. Key watch item: the source records do not disclose peak sales, exclusivity, or pricing for any approval, so commercial materiality cannot be verified and the batch should be treated as low-materiality flow pending full label and pathway detail.

5 total filings
· daily

Big Pharma Approvals — October 28, 2026

This digest covers six FDA actions dated 2026-10-22 to 2026-10-26 from the Big Pharma approvals stream, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 6 other approval actions by the data's classification (the classification is internally inconsistent: several entries are labeled FALLBACK or LLM FDA ANALYSIS, and the TALZENNA entry appears twice as a duplicate). Signals split 5 bullish, 0 bearish, 1 neutral. The highest-conviction item is AMGEN INC's AFLIBERCEPT-AYYH (PAVBLU), flagged as an NME approval with bullish strength 8/10, though its commercial metrics are NOT_DISCLOSED. No dominant therapeutic area cluster can be established because the source data does not specify indications for most entries, apart from identifiable ophthalmology (aflibercept), dermatology/immunology (risankizumab), oncology (talazoparib), and diabetes (insulin icodec). The primary watch item is data quality: the approval typings and duplicated entries limit confidence in the mix, and no sales, exclusivity, or pricing estimates are available beyond the single orphan designation on SKYRIZI.

6 total filings
· daily

Orphan Drug Approvals — October 28, 2026

This digest covers 4 FDA approvals dated October 21 to October 23, 2026, all classified under the Orphan Drug stream: 0 NMEs, 0 biosimilars, 0 label expansions, and 4 other-type actions. Signals are 3 bullish and 1 neutral, with no bearish signals. The approvals span AbbVie (SKYRIZI/risankizumab-rzaa, two entries), Novo Nordisk (AWIQLI FLEXTOUCH/insulin icodec), and Alexion (ULTOMIRIS/ravulizumab-cwvz), so no single therapeutic-area cluster is evident from the provided data. The highest-conviction item is the SKYRIZI supplemental BLA (BLA761262) for AbbVie, which carries Priority Review and Orphan Drug designations, though its labeling content and commercial scope are not disclosed. The principal watch item is that most approval records lack indication, sales, exclusivity, and pricing data, so commercial conclusions remain provisional until AbbVie, Novo Nordisk, and Alexion disclose labeling and launch details.

4 total filings
· daily

New Drug Approvals (Original) — October 28, 2026

This period recorded 6 FDA approvals on the New Drug Approvals stream, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 6 classified as other (the provided data labels the approval type as FALLBACK across all six). The two bullish signals both come from aflibercept-class approvals: Amgen Inc's AFLIBERCEPT-AYYH (PAVBLU) and Sandoz Inc's AFLIBERCEPT-ABZV (ENZEEVU), each rated 8/10 for strength and materiality, though the underlying data describes them as NME approvals while the summary field is inconsistent with the stated type mix. The remaining four approvals (valganciclovir hydrochloride from Alembic, teriparatide from Dr. Reddy's, trimethoprim from Bionpharma, amlodipine besylate from Cadila Pharmaceuticals) are neutral, rated 5/10, and described as biosimilar approvals in their summaries despite being classified as other. Commercial data (peak sales, exclusivity, pricing power, market position) is NOT_DISCLOSED for all six, so no quantitative investment sizing is supported. The key watch item is the classification inconsistency: several approvals described as biosimilars are generic-type molecules, and the two aflibercept approvals carry the highest signal weight in a period where most commercial inputs are missing.

6 total filings
· daily

New Federal Contractors — October 28, 2026

This period's digest covers a single new federal contract totaling $52,077,795 in obligations, awarded to The Bizzell Group LLC by the Department of Labor for the Guthrie Job Corps Center. The award is fully civilian with zero defense-related exposure, placing it in workforce development rather than the DOD budget stream that drives most sector investment theses. The dominant theme is a small-business set-aside vocational training contract, and the highest-conviction read is its operational durability: roughly 88% of obligated funds ($45,738,862) have already been outlaid, with a current end date of 2027-06-30. The primary watch item is whether the recipient is publicly traded, which the data does not establish, so investment relevance cannot be confirmed; option exercise decisions against the $82,384,110 base-plus-options value are the key forward trigger.

1 total filings
· daily

Significant Contract Modifications ($10M+) — October 28, 2026

This digest covers a single significant contract modification record totaling $52,077,795 in obligations, with zero defense-related awards and the entire amount sitting in civilian territory. The sole award is to The Bizzell Group LLC (Hyattsville, MD) from the Department of Labor for the Guthrie Job Corps Center, a firm fixed-price small business set-aside with a $82,384,110 base-plus-options value. The dominant theme is civilian workforce and vocational training funding rather than defense procurement, so no defense-sector signals apply. The highest-conviction observation is that roughly 88% of the obligated $52,077,795 ($45,738,862) has already been outlayed, which points to a largely disbursed, single-site revenue stream. The key watch item is whether option exercises close the gap between the current obligation and the $82,384,110 base-plus-options value, and whether the 2027-06-30 end date is extended toward 2028-06-30. Public-market exposure cannot be confirmed from the data, so investment relevance remains unverified.

1 total filings
· daily

Contract Deobligations Alert — October 28, 2026

This digest covers a single federal contract record: The Bizzell Group LLC's $52,077,795 total obligation from the Department of Labor for the Guthrie Job Corps Center, drawn from a $82,384,110 base-plus-options value. The award is entirely civilian (0 of 1 defense-related) and sits in workforce development and vocational training rather than in any defense or technology budget line. Approximately $45,738,862, or roughly 88% of the current obligation, has already been outlayed, so the remaining revenue runway is limited unless options are exercised. The most credible signal is the contract's small-business and HUBZone structure, which indicates a policy-driven award rather than a competitive moat. The principal watch item is whether the Department of Labor exercises options and extends the current 2027-06-30 end date toward the potential 2028-06-30 end. Investment relevance is unconfirmed because the data does not establish whether The Bizzell Group is publicly traded.

1 total filings
· daily

Contract Option Exercises — October 28, 2026

This digest covers a single federal contract option-exercise record totaling $52,077,795 in obligations, with zero defense-related awards and therefore a 0% defense / 100% civilian split. The dominant theme is Department of Labor workforce development, specifically the Job Corps program, where The Bizzell Group LLC holds a firm fixed price, total small business set-aside contract for the Guthrie Job Corps Center. The highest-conviction observation is the contract's favorable disbursement profile, with $45,738,862 already outlayed (roughly 88% of the obligation), which suggests limited remaining unfunded exposure. The principal watch item is the pending option exercise and end-date extension decision, with the current end date of 2027-06-30 potentially extending to 2028-06-30, and the investment relevance remains unclear because the data does not establish whether The Bizzell Group is publicly traded. Average signal strength across the stream is 4.0/10, indicating a low-materiality, neutral record.

1 total filings
· daily

High-Value Federal Grants ($5M+) — October 28, 2026

This digest covers a single federal award in the High-Value Federal Grants stream, totaling $52,077,795 in obligations within a period of October 28, 2026 only. The award is civilian, with zero defense-related contracts, and is concentrated in Department of Labor workforce training through the Guthrie Job Corps Center. The Bizzell Group LLC (Hyattsville, MD) holds the award on a firm fixed-price, small-business set-aside basis, with $45,738,862 already outlayed (roughly 88% of obligated funds). The highest-conviction takeaway is the award's predictable, fixed-price revenue profile under a set-aside, but the investment relevance is limited because the recipient's public-market status is not established by the data. The key watch item is the option exercise and end-date extension path from the current 2027-06-30 end toward the 2028-06-30 potential end, which determines whether the base-plus-options value of $82,384,110 is realized.

1 total filings
· daily

General Federal Contracts — October 28, 2026

This digest covers a single federal award totaling $52,077,795 in obligations, all from a civilian agency with zero defense-related records in the period (October 28, 2026). The dominant theme is Department of Labor workforce development, specifically a Job Corps center contract held by The Bizzell Group LLC of Hyattsville, MD. The highest-conviction read is that the contract is substantially funded, with roughly 88% of obligated dollars ($45,738,862) already outlayed against a $82,384,110 base-plus-options value, indicating a durable but modest revenue stream. The primary watch item is whether the Department of Labor exercises remaining options and extends the current 2027-06-30 end date toward the 2028-06-30 potential end. Investment relevance is limited because the data does not establish whether The Bizzell Group is publicly traded, and the award is neutral in signal strength (4/10, materiality 3/10).

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 28, 2026

Across the 12 filings for the S&P 500 Technology stream, the dominant theme is strong top-line momentum paired with a widening gap between GAAP and non-GAAP profitability. Cadence (revenue +22.0% YoY), Fortinet (revenue +20% YoY, billings +29%), KLA (revenue +28.9% YoY), ServiceNow (revenue +20.5% YoY) and Microsoft (revenue +19% YoY) all reported solid growth, but several growth figures were flattered by non-operating items: Microsoft's GAAP EPS growth of 32% compares with 18% non-GAAP, largely because other income swung from a $3.66B expense to a $38M gain. ServiceNow's GAAP operating income fell 32.7% YoY despite 20.5% revenue growth, as subscription cost of revenue rose 58.3%. Forward indicators are mixed: ServiceNow guided Q4 cRPO growth to 18.5% versus 20.5% in Q3, signaling deceleration, while Fortinet raised full-year revenue guidance to roughly 20% growth. Capital intensity is rising, with Microsoft's property and equipment capex more than doubling to $39.4B and KLA's quarterly capex rising to $195M from $89M. Insider activity was net positive, with Accenture's Chair and CEO buying roughly $2.7M of shares in aggregate and a director buying about $200K. Cash has been deployed heavily into M&A and buybacks, with Cadence paying $2.14B for business combinations and $800M in repurchases, and ServiceNow spending $9.17B on business combinations while long-term debt rose to $5.44B from $1.49B. Accenture's 'Chair and CEO' transaction data and the Oracle 8-K (where substantive figures sit in an unincluded exhibit) limit the depth of analysis for those names.

8 high priority 4 medium 12 total filings